Literature DB >> 7531515

A point mutation in the granulocyte colony-stimulating factor receptor (G-CSF-R) gene in a case of acute myeloid leukemia results in the overexpression of a novel G-CSF-R isoform.

F Dong1, M van Paassen, C van Buitenen, L H Hoefsloot, B Löwenberg, I P Touw.   

Abstract

A novel human granulocyte colony-stimulating factor (G-CSF) receptor isoform, designated SD, has been identified in which the distal C-terminal cytoplasmic region, previously shown to be essential for maturation signalling, is substituted by an altered C-terminus. The SD receptor has a high affinity for G-CSF and retains the membrane-proximal cytoplasmic region known to be sufficient for proliferative signalling. Nonetheless, the SD isoform lacks the ability to transduce growth signals in murine BAF3 cells and, in contrast to the wild-type G-CSF receptor, is scarcely capable of activating JAK2 kinase. Expression of SD receptor was found to be low in normal granulocytes, but was significantly increased in a patient with acute myeloid leukemia (AML). The leukemic cells of this patient harbour a point mutation in the SD splice donor site of the G-CSF receptor gene. These findings provide the first evidence that mutations in the G-CSF receptor gene can occur in certain cases of clinical de novo AML. The possible contribution of defective G-CSF receptor signalling to leukemogenesis is discussed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7531515

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  13 in total

Review 1.  Biology and significance of the JAK/STAT signalling pathways.

Authors:  Hiu Kiu; Sandra E Nicholson
Journal:  Growth Factors       Date:  2012-02-20       Impact factor: 2.511

2.  Prevalence of a new auto-activating colony stimulating factor 3 receptor mutation (CSF3R-T595I) in acute myeloid leukemia and severe congenital neutropenia.

Authors:  Renée Beekman; Marijke Valkhof; Paulette van Strien; Peter J M Valk; Ivo P Touw
Journal:  Haematologica       Date:  2013-03-18       Impact factor: 9.941

Review 3.  Cytokine receptor splice variants in hematologic diseases.

Authors:  Borwyn Wang; Hrishikesh Mehta
Journal:  Cytokine       Date:  2019-12-06       Impact factor: 3.861

4.  Molecular emergence of acute myeloid leukemia during treatment for acute lymphoblastic leukemia.

Authors:  J G Blanco; T Dervieux; M J Edick; P K Mehta; J E Rubnitz; S Shurtleff; S C Raimondi; F G Behm; C H Pui; M V Relling
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-28       Impact factor: 11.205

5.  Granulocyte colony-stimulating factor preferentially stimulates proliferation of monosomy 7 cells bearing the isoform IV receptor.

Authors:  Elaine M Sloand; Agnes S M Yong; Shakti Ramkissoon; Elena Solomou; Tullia C Bruno; Sonnie Kim; Monika Fuhrer; Sachiko Kajigaya; A John Barrett; Neal S Young
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-15       Impact factor: 11.205

6.  Combination therapy with sorafenib and S-1 for renal cell carcinoma producing granulocyte colony-stimulating factor.

Authors:  Yoko Kyono; Tatsuya Takayama; Mana Kinoshita; Yutaka Kurita; Soichi Mugiya; Satoshi Baba; Seiichiro Ozono
Journal:  Int J Clin Oncol       Date:  2010-09-16       Impact factor: 3.402

Review 7.  Systems approach to phagocyte production and activation: neutrophils and monocytes.

Authors:  Hrishikesh M Mehta; Taly Glaubach; Seth Joel Corey
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

Review 8.  G-CSF and GM-CSF in Neutropenia.

Authors:  Hrishikesh M Mehta; Michael Malandra; Seth J Corey
Journal:  J Immunol       Date:  2015-08-15       Impact factor: 5.422

Review 9.  Granulocyte colony-stimulating factor: molecular mechanisms of action during steady state and 'emergency' hematopoiesis.

Authors:  Athanasia D Panopoulos; Stephanie S Watowich
Journal:  Cytokine       Date:  2008-04-08       Impact factor: 3.861

Review 10.  Mathematical modeling as a tool for planning anticancer therapy.

Authors:  Andrzej Swierniak; Marek Kimmel; Jaroslaw Smieja
Journal:  Eur J Pharmacol       Date:  2009-10-13       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.